22 results
8-K
EX-99.1
TSBX
Turnstone Biologics Corp
13 May 24
Turnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
5:03pm
within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include
10-K
2023 FY
TSBX
Turnstone Biologics Corp
21 Mar 24
Annual report
8:51pm
clinical trials;
initiation of investigations by U.S. and foreign regulators;
costs to defend the related litigation;
diversion of management’s time … in litigation or arbitration, any of which would be time-consuming and expensive;
collaborators may seek to amend or modify the terms of any
10-K
2023 FY
EX-4.3
TSBX
Turnstone Biologics Corp
21 Mar 24
Annual report
8:51pm
. They may also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might benefit
8-K
EX-99.1
im8kq0wnv8 pxz
21 Mar 24
Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights
5:14pm
10-Q
m7atf
1 Sep 23
Quarterly report
4:39pm
424B4
yvt7 zo55fbc7xjl
21 Jul 23
Prospectus supplement with pricing info
7:14pm
S-1/A
bd9d2cgtz 2hv5auiw
23 Jun 23
IPO registration (amended)
9:49pm
S-1
EX-10.2
h1js5oj7a78
12 Jun 23
IPO registration
4:28pm
S-1
dj1wm9yd
12 Jun 23
IPO registration
4:28pm
S-1
EX-10.9
o1m8r xln9b3llig
12 Jun 23
IPO registration
4:28pm
S-1
EX-2.1
z4nncxg65g
12 Jun 23
IPO registration
4:28pm
S-1
EX-10.8
2moox
12 Jun 23
IPO registration
4:28pm
DRS
EX-2.1
i4ms3ico9f
15 May 23
Draft registration statement
12:00am
DRS
EX-10.8
51kgzvqf
15 May 23
Draft registration statement
12:00am
DRS
EX-10.9
bob6 jzsrm7
15 May 23
Draft registration statement
12:00am